Kaka J S
Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Food Chem Toxicol. 1991 Jun;29(6):419-23. doi: 10.1016/0278-6915(91)90083-j.
This study investigated the feasibility of using concurrent iv administration of antipyrine (15 mg/kg body weight) and bromosulphophthalein (BSP; 25 mg/kg) in the rat. Antipyrine is used as an index of hepatic drug metabolism and BSP is used to assess hepatic blood flow. Plasma concentrations of BSP were described using biexponential phases, while antipyrine plasma concentrations were monoexponential. No significant difference was observed between antipyrine pharmacokinetic parameters in concurrent BSP rats when compared with controls. There was also no significant difference between BSP pharmacokinetic parameters in concurrent antipyrine rats when compared with controls, except in the alpha value (P less than 0.05). This indicates that BSP distribution may be affected by concurrent antipyrine administration. Therefore, simultaneous administration of both substrates is not acceptable to study hepatic blood flow. Another iv combination dose (25 mg BSP/kg body weight, followed by 15 mg antipyrine/kg 0.5 hr later) and a dose of 15 mg antipyrine/kg body weight only was administered to rats pretreated with phenobarbital (90 mg/kg body weight) for 6 days. Pharmacokinetic parameters of BSP, beta, k21, k23 and plasma clearance, in the pretreated rats were significantly different from non-pretreated rats. No significant difference was observed in the pharmacokinetic parameters of antipyrine between the combination dose and antipyrine dose in the phenobarbital-pretreated rats. The half-lives of antipyrine in both pretreated groups decreased approximately by 70%, while the clearance increased four times compared with controls. The volume of distribution in these animals did not change as a result of phenobarbital pretreatment. This suggests that a 25 mg BSP/kg body weight dose followed by 15 mg antipyrine/kg 0.5 hr later may be a feasible approach to study liver blood flow, as well as hepatic efficiency in rats.
本研究调查了在大鼠中同时静脉注射安替比林(15毫克/千克体重)和磺溴酞钠(BSP;25毫克/千克)的可行性。安替比林用作肝药物代谢指标,BSP用于评估肝血流量。BSP的血浆浓度用双指数相描述,而安替比林的血浆浓度为单指数。与对照组相比,同时注射BSP的大鼠中安替比林的药代动力学参数无显著差异。与对照组相比,同时注射安替比林的大鼠中BSP的药代动力学参数也无显著差异,但α值除外(P小于0.05)。这表明同时注射安替比林可能会影响BSP的分布。因此,同时给予两种底物来研究肝血流量是不可行的。另一种静脉注射组合剂量(25毫克BSP/千克体重,随后0.5小时后注射15毫克安替比林/千克)和仅15毫克安替比林/千克体重的剂量给予用苯巴比妥(90毫克/千克体重)预处理6天的大鼠。预处理大鼠中BSP、β、k21、k23和血浆清除率的药代动力学参数与未预处理大鼠有显著差异。在苯巴比妥预处理的大鼠中,组合剂量和安替比林剂量之间的安替比林药代动力学参数无显著差异。两个预处理组中安替比林的半衰期与对照组相比均降低了约70%,而清除率增加了四倍。这些动物的分布容积并未因苯巴比妥预处理而改变。这表明先给予25毫克BSP/千克体重剂量,0.5小时后再给予15毫克安替比林/千克可能是研究大鼠肝血流量以及肝效率的一种可行方法。